Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

2.

Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.

de Montigny S, Adamson BJS, Mâsse BR, Garrison LP Jr, Kublin JG, Gilbert PB, Dimitrov DT.

Sci Rep. 2018 Apr 17;8(1):6066. doi: 10.1038/s41598-018-24268-4.

3.

Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa.

Dietrich JJ, Lazarus E, Andrasik M, Hornschuh S, Otwombe K, Morgan C, Isaacs AJ, Huang Y, Laher F, Kublin JG, Gray GE; HVTN 915 study team.

AIDS Behav. 2018 Jul;22(7):2312-2321. doi: 10.1007/s10461-018-2080-y.

PMID:
29594618
4.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

5.

A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation.

Murphy SC, Duke ER, Shipman KJ, Jensen RL, Fong Y, Ferguson S, Janes HE, Gillespie K, Seilie AM, Hanron AE, Rinn L, Fishbaugher M, VonGoedert T, Fritzen E, Kappe SH, Chang M, Sousa JC, Marcsisin SR, Chalon S, Duparc S, Kerr N, Möhrle JJ, Andenmatten N, Rueckle T, Kublin JG.

J Infect Dis. 2018 Feb 14;217(5):693-702. doi: 10.1093/infdis/jix613.

PMID:
29216395
6.

Utilizing gnotobiotic models to inform the role of the microbiome in vaccine response heterogeneity.

Cram JA, Hager KW, Kublin JG.

Curr Opin HIV AIDS. 2018 Jan;13(1):1-8. doi: 10.1097/COH.0000000000000422. Review.

PMID:
29176431
7.

The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.

Adamson BJS, Carlson JJ, Kublin JG, Garrison LP.

Vaccines (Basel). 2017 May 24;5(2). pii: E13. doi: 10.3390/vaccines5020013.

8.

Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs.

Hanron AE, Billman ZP, Seilie AM, Olsen TM, Fishbaugher M, Chang M, Rueckle T, Andenmatten N, Greenhouse B, Arinaitwe E, Rek J, Das S, Domingo GJ, Shipman K, Kappe SH, Kublin JG, Murphy SC.

Malar J. 2017 May 19;16(1):208. doi: 10.1186/s12936-017-1863-3.

9.

Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects.

Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH.

Sci Transl Med. 2017 Jan 4;9(371). pii: eaad9099. doi: 10.1126/scitranslmed.aad9099.

PMID:
28053159
10.

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.

Dimitrov D, Kublin JG, Ramsey S, Corey L.

EBioMedicine. 2015 Nov 5;2(12):2062-9. doi: 10.1016/j.ebiom.2015.11.009. eCollection 2015 Dec.

11.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.

Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29. Review.

12.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

13.

Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi.

Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante AA, Plowe CV, Laufer MK, Takala-Harrison S.

J Infect Dis. 2015 Sep 1;212(5):694-701. doi: 10.1093/infdis/jiv078. Epub 2015 Feb 11.

14.

A new model for catalyzing translational science: the early stage investigator mentored research scholar program in HIV vaccines.

Adamson BJ, Fuchs JD, Sopher CJ, Flood DM, Johnson RP, Haynes BF, Kublin JG; NIAID HIV Vaccine Trials Network.

Clin Transl Sci. 2015 Apr;8(2):166-8. doi: 10.1111/cts.12249. Epub 2014 Dec 30.

15.

Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.

Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23.

16.

Tuberculosis vaccines and prevention of infection.

Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG.

Microbiol Mol Biol Rev. 2014 Dec;78(4):650-71. doi: 10.1128/MMBR.00021-14. Review.

17.

Enhancing diversity in the public health research workforce: the research and mentorship program for future HIV vaccine scientists.

Sopher CJ, Adamson BJ, Andrasik MP, Flood DM, Wakefield SF, Stoff DM, Cook RS, Kublin JG, Fuchs JD.

Am J Public Health. 2015 Apr;105(4):823-30. doi: 10.2105/AJPH.2014.302076. Epub 2014 Aug 14.

18.

The immune space: a concept and template for rationalizing vaccine development.

Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1017-22. doi: 10.1089/AID.2014.0040. Epub 2014 Jun 26.

19.

HIV-1 infection and antibodies to Plasmodium falciparum in adults.

Hasang W, Dembo EG, Wijesinghe R, Molyneux ME, Kublin JG, Rogerson S.

J Infect Dis. 2014 Nov 1;210(9):1407-14. doi: 10.1093/infdis/jiu262. Epub 2014 May 3.

PMID:
24795481
20.

Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'.

Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN.

AIDS. 2013 Nov 13;27(17):2826-7. doi: 10.1097/QAD.0000000000000002. No abstract available.

PMID:
24384634
21.

The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.

Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker LG.

Int J STD AIDS. 2014 Apr;25(5):332-40. doi: 10.1177/0956462413506892. Epub 2013 Oct 8.

22.

Lessons learned from HIV vaccine clinical efficacy trials.

Day TA, Kublin JG.

Curr HIV Res. 2013 Sep;11(6):441-9. Review.

23.

Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?

Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN.

AIDS. 2013 Sep 24;27(15):2494-6. doi: 10.1097/01.aids.0000432463.23508.a2. No abstract available.

PMID:
24029738
24.

Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives.

Andrasik MP, Karuna ST, Nebergall M, Koblin BA, Kublin JG; NIAID HIV Vaccine Trials Network.

Vaccine. 2013 Sep 13;31(40):4398-405. doi: 10.1016/j.vaccine.2013.07.003. Epub 2013 Jul 13.

25.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2013 Sep 1;208(5):818-29. doi: 10.1093/infdis/jit236. Epub 2013 Jul 8.

26.

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.

Kublin JG, Morgan CA, Day TA, Gilbert PB, Self SG, McElrath MJ, Corey L.

Clin Investig (Lond). 2012 Mar;2(3):245-254.

27.

Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?

Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN; HIV Viral Load Working Group.

AIDS. 2013 Mar 27;27(6):981-9. doi: 10.1097/QAD.0b013e32835cb927.

28.

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP, Huang Y, Spies GA, De Rosa SC, McElrath MJ.

J Clin Invest. 2012 Jan;122(1):359-67. doi: 10.1172/JCI60202. Epub 2011 Dec 27.

29.

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN 503/Phambili study team.

Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Erratum in: Lancet Infect Dis. 2011 Jul;11(7):495.

30.

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.

PLoS One. 2011 Apr 13;6(4):e18526. doi: 10.1371/journal.pone.0018526.

31.

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV.

J Infect Dis. 2010 Jan 1;201(1):132-41. doi: 10.1086/648591.

PMID:
19929694
32.

Post-step modifications for research on HIV vaccines.

Corey L, McElrath MJ, Kublin JG.

AIDS. 2009 Jan 2;23(1):3-8. doi: 10.1097/QAD.0b013e32830e6d6d. Review. No abstract available.

33.

Challenges in the prevention, diagnosis, and treatment of malaria in human immunodeficiency virus infected adults in sub-Saharan Africa.

Brentlinger PE, Behrens CB, Kublin JG.

Arch Intern Med. 2007 Sep 24;167(17):1827-36. Review.

PMID:
17893303
34.

Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa.

Abu-Raddad LJ, Patnaik P, Kublin JG.

Science. 2006 Dec 8;314(5805):1603-6. Erratum in: Science. 2007 Feb 2;315(5812):598.

35.
36.

HIV infection and malaria--understanding the interactions.

Kublin JG, Steketee RW.

J Infect Dis. 2006 Jan 1;193(1):1-3. Epub 2005 Nov 18. No abstract available.

PMID:
16323123
37.
38.

Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children.

Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, Molyneux ME, Plowe CV, Smith PJ.

Antimicrob Agents Chemother. 2005 Sep;49(9):3601-6.

39.

Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi.

Patnaik P, Jere CS, Miller WC, Hoffman IF, Wirima J, Pendame R, Meshnick SR, Taylor TE, Molyneux ME, Kublin JG.

J Infect Dis. 2005 Sep 15;192(6):984-91. Epub 2005 Aug 12.

PMID:
16107950
40.

Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria.

Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, Molyneux ME, Plowe CV, Smith PJ.

Am J Trop Med Hyg. 2005 Mar;72(3):267-72.

PMID:
15772319
41.

Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study.

Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, Pendame R, Taylor TE, Molyneux ME.

Lancet. 2005 Jan 15-21;365(9455):233-40.

PMID:
15652606
42.

Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites.

Bates SJ, Winstanley PA, Watkins WM, Alloueche A, Bwika J, Happi TC, Kremsner PG, Kublin JG, Premji Z, Sibley CH.

J Infect Dis. 2004 Nov 15;190(10):1783-92. Epub 2004 Oct 18.

PMID:
15499534
43.

A prospective study of bloodstream infections as cause of fever in Malawi: clinical predictors and implications for management.

Peters RP, Zijlstra EE, Schijffelen MJ, Walsh AL, Joaki G, Kumwenda JJ, Kublin JG, Molyneux ME, Lewis DK.

Trop Med Int Health. 2004 Aug;9(8):928-34.

44.

Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial.

Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JG, Lang T, Missinou MA, Mkandala C, Oduola AM, Premji Z, Robertson L, Sowunmi A, Ward SA, Winstanley PA.

Lancet. 2004 Jun 5;363(9424):1843-8.

PMID:
15183620
45.

Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study.

Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, Chimpeni P, Molyneux ME, Taylor TE.

BMJ. 2004 Mar 6;328(7439):545. Epub 2004 Feb 2. Erratum in: BMJ. 2004 Mar 27;328(7442):762.

46.

Prevalence and indicators of HIV and AIDS among adults admitted to medical and surgical wards in Blantyre, Malawi.

Lewis DK, Callaghan M, Phiri K, Chipwete J, Kublin JG, Borgstein E, Zijlstra EE.

Trans R Soc Trop Med Hyg. 2003 Jan-Feb;97(1):91-6.

PMID:
12886812
47.

Retinal changes in adults with cerebral malaria.

Beare NA, Lewis DK, Kublin JG, Harding SP, Zijlstra EE, Molyneux ME.

Ann Trop Med Parasitol. 2003 Apr;97(3):313-5. No abstract available.

PMID:
12803862
48.

Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi.

Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV.

J Infect Dis. 2003 Jun 15;187(12):1870-5. Epub 2003 May 21.

PMID:
12792863
49.

Clinical indicators of mycobacteraemia in adults admitted to hospital in Blantyre.

Lewis DK, Peters R, Schijffelen MJ, Joaki G, Walsh AL, Kublin JG, Kumwenda J, Kampondeni S, Molyneux ME, Zijlstra EE.

Malawi Med J. 2003 Jun;15(2):56-60.

50.

Clinical indicators of mycobacteraemia in adults admitted to hospital in Blantyre, Malawi.

Lewis DK, Peters RP, Schijffelen MJ, Joaki GR, Walsh AL, Kublin JG, Kumwenda J, Kampondeni S, Molyneux ME, Zijlstra EE.

Int J Tuberc Lung Dis. 2002 Dec;6(12):1067-74.

PMID:
12546114

Supplemental Content

Loading ...
Support Center